EU regulator to review reports of suicidal thoughts and weight loss drugs

The agency began its review into the class of weight loss and diabetes drugs, known as GLP-1 receptor agonists, last July after Iceland's health regulator flagged three cases of patients thinking about suicide or self-harm after using Novo's drugs - diabetes drug Ozempic and weight-loss treatment Saxenda.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/kHWSYve
via gqrds

Comments

Popular posts from this blog

Women in India Report Higher Sleep Deprivation Than Men

Nadda reviews healthcare delivery mechanisms in Rajasthan, Maharashtra

Ayush no longer at margins but at centre of global health discourse: Prataprao Jadhav